Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients
Main Article Content
Keywords
hospitalization; sarcoidosis; SARS-COV-2
Abstract
Background and aim: There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.
Methods: We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires.
Results: 530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection.
Conclusions: The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.
References
1. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201(8): e26-e51.
2. Papiris SA, Campo I, Mariani F, et al. COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study. ERJ Open Res 2023; 9 (1) : 00199-2022.
3. Papiris SA, Bouros D, Markopoulou K, et al. Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial "impact" beyond any expectation. Eur Respir J 2021; 57 (3): 2003111.
4. El Jammal T, Jamilloux Y, Gerfaud-Valentin M, Valeyre D, Sève P. Refractory Sarcoidosis: A Review. Ther Clin Risk Manag 2020; 16: 323-45.
5. Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020; 26 (5): 527-34.
6. Saidha S, Sotirchos ES, Eckstein C. Etiology of sarcoidosis: does infection play a role? Yale J Biol Med 2012; 85 (1): 133-41.
7. Nikoskelainen J, Hänninen P. Antibody response to Epstein-Barr virus in infectious mononucleosis. Infect Immun 1975; 11 (1): 42-51.
8. Shifera AS, Pockrandt C, Rincon N, et al. Identification of microbial agents in tissue specimens of ocular and periocular sarcoidosis using a metagenomics approach. F1000Res 2021; 10:820.
9. Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells 2021; 10(12): 3592.
10. Morgenthau AS, Levin MA, Freeman R, Reich DL, Klang E. Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARS‑CoV‑2. Lung 2020; 198 (5): 771-5.
11. Baughman RP, Lower EE, Buchanan M, et al. Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (4): e2020009.
12. Kahlmann V, Manansala M, Moor CC, Shahrara S, Wijsenbeek MS, Sweiss NJ. COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. Curr Opin Pulm Med 2021; 27( 5): 463-71.
13. Strykowski R, Patel DC, Neto MR, et al. Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study. BMJ Open Respir Res 2022; 9 (1): e001254.
14. Hadi YB, Sohail AH, Lakhani DA, Naqvi SF, Kupec JT, Pervez A. Outcomes of SARS-CoV-2 infection in patients with celiac disease: a multicenter research network study. Ann Gastroenterol 2022; 35 (2): 164-8.
15. Liu W, Liu Y, Xu Z, et al. Clinical characteristics and predictors of the duration of SARS-CoV-2 viral shedding in 140 healthcare workers. J Intern Med 2020; 288 (6): 725-36.
16. Capaccione KM, McGroder C, Garcia CK, Fedyna S, Saqi A, Salvatore MM. COVID-19-induced pulmonary sarcoid: A case report and review of the literature. Clin Imaging 2022; 83: 152-8.
17. Behbahani S, Baltz JO, Droms R, et al. Sarcoid-like reaction in a patient recovering from coronavirus disease 19 pneumonia. JAAD Case Rep 2020; 6 (9): 915-7.
18. Karakatsani A, Papakosta D, Rapti A, et al; Hellenic Interstitial Lung Diseases Group. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103 (8): 1122-9.
19. Edouard Mathieu, Hannah Ritchie, Lucas Rodés-Guirao, et al. “Greece: Coronavirus Pandemic Country Profile.” https://ourworldindata.org/coronavirus/country/greece
20. Desbois AC, Marques C, Lefèvre L, et al. Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. Clin Exp Rheumatol 2022; 40 (1): 195-6.
21. Sweiss NJ, Salloum R, Gandhi S, et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One 2010; 5 (2): e9088.
22. Lommatzsch M, Rabe KF, Taube C, et al. Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie (Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)). Pneumologie 2021; 75 (1): 19-30.
23. Ungprasert P, Crowson CS, Matteson EL. Sarcoidosis Increases Risk of Hospitalized Infection. A Population-based Study, 1976-2013. Ann Am Thorac Soc 2017; 14 (5): 676-81.
24. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health 2020; 65 (5): 533-46.
25. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-95.
26. Li J, Huang DQ, Zou B, et al Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021; 93 (3): 1449-58.
27. Papiris SA, Georgakopoulos A, Papaioannou AI, et al. Emerging phenotypes of sarcoidosis based on 18F-FDG PET/CT: a hierarchical cluster analysis. Expert Rev Respir Med 2020; 14 (2): 229-38.
28. Song X, Shao F, Lan X. The Onset of Sarcoidosis After COVID-19 Vaccination Revealed by the 18 F-FDG PET. Clin Nucl Med 2022; 47 (10): 869-71.
29. Albers CC, Metze D, Steinbrink K, Böhm M. Systemic Sarcoidosis with Cutaneous Tattoo Involvement Following COVID-19 Vaccination. Acta Derm Venereol 2023; 103: adv6244.
30. Shukla AK, Peter A, Bhargava JK, et al. Sarcoidosis presenting as bilateral optic neuritis after ChAdOx1 nCoV-19 vaccination. Monaldi Arch Chest Dis 2022; 93 (1).
31. Cazzato G, Ambrogio F, Foti C, et al. Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship? Diagnostics (Basel) 2023; 13 (7): 1286.
32. Mohaghegh F, Hatami P, Refaghat A, et al. Unmasking sarcoidosis following SARS-CoV-2 vaccination: A case report. Clin Case Rep 2022; 10 (12): e6660.
33. Numakura T, Murakami K, Tamada T, et al. A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review. Intern Med 2022; 61 (20): 3101-6.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
